Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moberg Pharma AB

www.mobergpharma.se

Latest From Moberg Pharma AB

US Health Market In 2019: Unfinished Business Leaves Lasting Impression

Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.

OTC Drugs Outlook 2019

Asia Deal Watch: Qpex Partners Its Experimental Antibiotics With Brii In Greater China

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Deals Asia Pacific

Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Deals Business Strategies

Moberg Sells Consumer Health Portfolio To Pay For Rx Research Focus

Moberg had been expanding its OTC portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands.
OTC Drugs Consumer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Moberg Derma AB
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Moberg Pharma AB
  • Senior Management
  • Anna Ljung, CEO
    Torbjörn Wärnheim, SVP, R&D
    Mark Beveridge, VP, Fin.
  • Contact Info
  • Moberg Pharma AB
    Phone: (46) 8 522 30 700
    Gustavslundsvägen 42
    Bromma
    Stockholm, SE-167 51
    Sweden
UsernamePublicRestriction

Register